Belsomra: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 5: Line 5:




Belsomra is a medication used to treat the inability to fall asleep or stay asleep (1).  While most other insomnia drugs, like Ambien and Lunesta, are GABA agonists and work to slow down neuronal firings, Belsomra is the first drug to target orexin (2).    Orexin, also known as hypocretin, is a neurotransmitter that binds to receptors in order to cause alertness and wakefulness.  By targeting these neurotransmitters, it cuts off the signals causing one to be awake, and will result in sleep (1).   
<scene name='74/746099/Belsomra/1'>Belsomra</scene> is a medication used to treat the inability to fall asleep or stay asleep (1).  While most other insomnia drugs, like Ambien and Lunesta, are GABA agonists and work to slow down neuronal firings, Belsomra is the first drug to target orexin (2).    Orexin, also known as hypocretin, is a neurotransmitter that binds to receptors in order to cause alertness and wakefulness.  By targeting these neurotransmitters, it cuts off the signals causing one to be awake, and will result in sleep (1).   




Line 23: Line 23:
<references/>
<references/>


3. First Orexin Receptor Antagonist Approved for Insomnia. AJN, American Journal of Nursing. 114(12):26, December 2014.
First Orexin Receptor Antagonist Approved for Insomnia.
AJN, American Journal of Nursing. 114(12):26, December 2014.


4. Krystal AD, Benca RM, Kilduff TS. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. J Clin Psychiatry 2013; 74(Suppl 1): 3–20.
Krystal AD, Benca RM, Kilduff TS. Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. J Clin Psychiatry 2013; 74(Suppl 1): 3–20.


5. Pagel, J. F., & Parnes, B. L. (2001). Medications for the Treatment of Sleep Disorders: An Overview. Primary Care Companion to The Journal of Clinical Psychiatry, 3(3), 118–125.
Pagel, J. F., & Parnes, B. L. (2001). Medications for the Treatment of Sleep Disorders: An Overview. Primary Care Companion to The Journal of Clinical Psychiatry, 3(3), 118–125.


6. Schwartz, J. R. ., & Roth, T. (2008). Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications. Current Neuropharmacology, 6(4), 367–378. http://doi.org/10.2174/157015908787386050
Schwartz, J. R. ., & Roth, T. (2008). Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications. Current Neuropharmacology, 6(4), 367–378. http://doi.org/10.2174/157015908787386050


7. Stahl, S.M. (2016) ‘Mechanism of action of suvorexant’, CNS Spectrums, 21(3), pp. 215–218. doi: 10.1017/S1092852916000225.
Stahl, S.M. (2016) ‘Mechanism of action of suvorexant’, CNS Spectrums, 21(3), pp. 215–218. doi: 10.1017/S1092852916000225.


8. T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, M. Yanagisawa Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding    
T. Sakurai, A. Amemiya, M. Ishii, I. Matsuzaki, R.M. Chemelli, H. Tanaka, S.C. Williams, J.A. Richardson, G.P. Kozlowski, S. Wilson, J.R. Arch, R.E. Buckingham, A.C. Haynes, S.A. Carr, R.S. Annan, D.E. McNulty, W.S. Liu, J.A. Terrett, N.A. Elshourbagy, D.J. Bergsma, M. Yanagisawa Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92 (1998), pp. 573–585.
behavior. Cell, 92 (1998), pp. 573–585.
Retrieved from "https://proteopedia.org/Belsomra"